Document is current

Article History

Received: 22 June 2022

Accepted: 6 February 2023

First Online: 1 March 2023

Change Date: 4 November 2024

Change Type: Update

Change Details: In table 2 age ranges were shown as references: Broad LGS: 31.4 [2–89]; 53% male Narrow LGS: 7.4 [2–14]; 52% male; 12 [4–43]; 63% male; 13 [3–34]; NR. It should be: Broad LGS: 31.4(2–89); 53% male; Narrow LGS: 7.4 (2–14); 52% male; 12 (4–43); 63% male; 13 (3–34); NR

Declarations

:

: Not applicable.

: Not applicable.

: AS reports personal fees and grants from Angelini Pharma, Desitin Arzneimittel, Eisai, Jazz/GW Pharmaceuticals companies, Marinus Pharma, Precisis, Takeda, UCB, UNEEG medical, and Zogenix. SZ reports research support from Epilepsy Research UK, Scottish Government Digital Health & Care, UCB Pharma, Dravet Syndrome UK, Dravet Syndrome Foundation, Tenovus Foundation and Glasgow Children’s Hospital Charity. He or his institution have received honoraria for consultancy work, educational symposia and advisory boards from GW Pharma, Zogenix, UCB, Encoded Therapeutics, Takeda and Eisai. PS reports personal fees and grants from Angelini Pharma, Eisai, Jazz Pharmaceuticals Biomarin, UCB, Proveca, and Zogenix. FR reports personal fees from Angelini Pharma, Arvelle Therapeutics, Eisai GmbH, GW Pharmaceuticals companies, and UCB and grants from the Detlev-Wrobel-Fonds for Epilepsy Research, the Deutsche Forschungsgemeinschaft, the LOEWE Programme of the State of Hesse, and the European Union. SSB reports personal fees from Eisai, Desitin Pharma, GW Pharmaceuticals companies, Ethypharm, UCB, and Zogenix.